New SEC Form D filing

EVIA Life Sciences Inc., 2026-11-02

A new SEC Form D private-offering notice from Tokyo, a $5,498,154 filer-stated offering target in Biotech. The source filing is one click away.

What this filing says

EVIA Life Sciences Inc. site↗ Verified via SEC Form D

Biotech company developing extracellular vesicle therapeutics using cell reprogramming technology, with a lead program targeting liver fibrosis and MASH.

Filed 2026-11-02Filed to raise $5,498,154First money in 2026-10-23Raised so far $700,002HQ (as filed) TokyoSector Biotech web-verified against the company’s own siteStage (inferred) EarlyCall status Non-US principal office
Source linked the Form D on EDGAR↗Website verified evialifesciences.com↗Named in the filing 4 executives & directors

This is a public SEC Form D private-offering notice, the filer's own statement to the SEC. Amounts are offering targets, not confirmed closes. Takeoff Radar pulls Form D nightly from EDGAR and links every filing to its source.

Other Form D filings from the same week

each with its own page and its own EDGAR source